Status:

COMPLETED

A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)

Lead Sponsor:

Stanford University

Collaborating Sponsors:

Bristol-Myers Squibb

Conditions:

Scleroderma, Diffuse

Scleroderma, Systemic

Eligibility:

All Genders

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

Systemic sclerosis (scleroderma) is an autoimmune connective tissue disease that involves the skin and other internal organs for which there are few effective treatment options. We hypothesize that tr...

Detailed Description

Systemic sclerosis is an autoimmune connective tissue disease of unknown etiology characterized by progressive fibrosis of the skin and internal organs, vascular damage, and autoantibody production. A...

Eligibility Criteria

Inclusion

  • Diagnosis of diffuse systemic sclerosis
  • age 18 years or older
  • Adequate renal, pulmonary, and cardiovascular function
  • Willingness to use effective contraception for the duration of the study if subject is of childbearing potential\


Exclusion

  • Other connective tissues diseases or overlap syndromes including MCTD, SLE, RA, eosinophilic fasciitis, and limited systemic sclerosis or morphea
  • Use of disease modifying agents including methotrexate, cyclosporine,azathioprine, mycophenolate mofetil, minocycline, doxycycline, minocycline, thalidomide, penicillamine, tamoxifen, colchicine, or investigational agent within 90 days of screening visit
  • HIV, Hepatitis B or Hepatitis C infection
  • use of prednisone greater than 10mg daily for 28 days prior to screening visit
  • women who are breastfeeding or pregnant

Key Trial Info

Start Date :

November 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2011

Estimated Enrollment :

10 Patients enrolled

Trial Details

Trial ID

NCT00442611

Start Date

November 1 2008

End Date

June 1 2011

Last Update

October 31 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Stanford University School of Medicine

Stanford, California, United States, 94305

A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma) | DecenTrialz